Entera Bio Ltd share price logo

Entera Bio Ltd Share Price

NASDAQ: ENTX

Small Cap

$1.18

as on

Entera Bio Ltd Stock Performance

as on April 17, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $1.13
    $1.22
    downward going graph

    4.24%

    Downside

    3.39%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.91
    $3.22
    downward going graph

    22.88%

    Downside

    172.88%

    Upside

    downward going graph

Entera Bio Ltd share price movements today

Previous Close
$1.18
Open
$1.21
Volume
363.2K
Day's Low - High
$1.13 - $1.22
52 Week Low - High
$0.91 - $3.22

Entera Bio Ltd Historical Returns

1 Month Return
-13.04 %
3 Month Return
-25.93 %
1 Year Return
-32.96 %
3 Year Return
+ 40.7 %
5 Year Return
-60 %

Entera Bio Ltd Stock Fundamentals & Key Indicators

Check Entera Bio Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$65.3M

EPS (TTM)

-0.68

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-11.5M

Revenue (TTM)

42.0K

Profit Margin

0.00%

Return On Equity TTM

-108.01%

Entera Bio Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Entera Bio Ltd with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$65.3M-60%NA0.00%
BUY$42.7B130.51%136.818.45%
BUY$110.8B98.57%28.4232.94%
NA$36.8BNA129.845.37%
BUY$78.9B48.43%17.9831.41%

Stock Returns calculator for Entera Bio Ltd Stock including INR - Dollar returns

The Entera Bio Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Entera Bio Ltd investment value today

Current value as on today

₹71,831

Returns

-₹28,169

(-28.17%)

Returns from Entera Bio Ltd Stock

-₹34,078 (-34.08%)

Dollar Impact

₹5,909 (+5.91%)

Analyst Recommendation on Entera Bio Ltd Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Entera Bio Ltd. Average target price of $10

Entera Bio Ltd Share Price Target

Get share price movements and forecasts by analysts on Entera Bio Ltd.

What analysts predicted

88.2%UPSIDE

Target Price

$10

Current Price

$1.18

Analyzed by

7 Analysts

Target

$10.00

Entera Bio Ltd target price $10, a slight upside of 88.2% compared to current price of $1.18. According to 7 analysts rating.

Entera Bio Ltd Stock’s Investor Sentiment and Interest

Search interest for Entera Bio Ltd Stock has increased by 1000% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:1000% versus previous 30 day period

Entera Bio Ltd Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
4
-
0
0
0
0
-
-
-
Gross Profit
0
0
0
0
-
-
-
0
0
0
Operating Income
-2
-1
-2
-2
-3
-2
-2
-2
-3
-3
EBITDA
-2
-1
-2
-2
-3
-2
-2
-2
-3
-3
Interest Expense
-
0
-
-
-
0
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-2
-1
-2
-2
-3
-2
-2
-2
-3
-3
Income Tax Expense
0
2
0
0
-6
0
-
-
-
-
Net Income
-2
-1
-2
-2
-3
-2
-2
-2
-3
-3
Net Profit Margin
0.00%
-44.51%
0.00%
-3763.16%
-7192.86%
-2875.61%
-6111.90%
0.00%
0.00%
0.00%

Entera Bio Ltd Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-5
11
-10
-11
-11
-12
-13
-8
-9
-11
EBITDA
-5
-11
-10
-10
-10
-12
-12
-8
-9
-11
Interest Expense
-
-
-
0
1
0
26
-
-
-
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-1
-11
-10
-10
-9
-12
-12
-8
-9
-11
Income Tax Expense
-
0
0
0
0
0
0
0
0
11
Net Income
-1
-11
-10
-10
-9
-12
-13
-8
-9
-11
Net Profit Margin
0.00%
0.00%
-2060.80%
-4574.15%
-2735.07%
-2134.33%
-9754.48%
-63492.86%
-5271.27%
-27235.71%

Entera Bio Ltd Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-1
-2
-2
-3
-2
-2
-2
-3
-3
Operating Cash Flow
-2
-1
-1
-2
-1
-1
-1
-2
-2
Investing Cash Flow
0
-
-
-
0
0
0
0
0
Financing Cash Flow
5
0
1
0
3
13
0
0
0
Change in Cash
3
-1
0
-2
1
11
-1
-2
-1

Entera Bio Ltd Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-11
-10
-10
-11
-12
-13
-8
-9
-11
Operating Cash Flow
-4
-9
-8
-10
-9
-12
-7
-6
-7
Investing Cash Flow
1
-4
3
0
0
0
0
0
0
Financing Cash Flow
11
9
12
4
25
0
6
4
13
Change in Cash
7
-4
7
-6
16
-12
-1
-2
6

Global Institutional Holdings in Entera Bio Ltd

Funds
Holdings
Northern Trust Corp
0.32%
Point72 Asset Management, L.P.
2.57%
Renaissance Technologies Corp
0.23%
Citadel Advisors Llc
0.09%
Parkman Healthcare Partners LLC
0.59%

Entera Bio Ltd News & Key Events

  • img

    Today's Timeline - 09 February

    Mon, 09:31 PM

    -

    Entera Bio appoints Geno J. Germano as Chairman of the Board, effective February 4, 2026.

Insights on Entera Bio Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -3.2M → -3.01M (in $), with an average increase of 6.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 61.9% return, outperforming this stock by 23.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 42.1% return, outperforming this stock by 76.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ENTX stock has moved down by -14.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 82.0K → 42.0K (in $), with an average decrease of 48.8% per quarter

About Entera Bio Ltd

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
OrganisationEntera Bio Ltd
HeadquartersKiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
IndustryBiotechnology
CEOMs. Miranda J. Toledano M.B.A.
E-voting on sharesClick here to vote

Key Management of Entera Bio Ltd

Name

Title

Dr. Constantin Itin Ph.D., R.Ph.

Head of Biopharmaceutics & Bioanalytics

Ms. Miranda J. Toledano M.B.A.

CEO & Director

Dr. Hillel Galitzer M.B.A., Ph.D.

Chief Operating Officer

Dr. Gregory Burshtein Ph.D.

Chief of Research & Development

Ms. Dana Yaacov-Garbeli CPA

Chief Financial Officer

Dr. Rachel B. Wagman

Chief Clinical Advisor

Ms. Cherin Smith

Executive VP & Head of Clinical Operations

FAQs

What is Entera Bio Ltd share price today?

Entera Bio Ltd share price today is $1.18 as on at the close of the market. Entera Bio Ltd share today touched a day high of $1.22 and a low of $1.13.

What is the 52 week high and 52 week low for Entera Bio Ltd share?

Entera Bio Ltd share touched a 52 week high of $3.22 on and a 52 week low of $0.91 on . Entera Bio Ltd stock price today i.e. is closed at $1.18,which is 63.35% down from its 52 week high and 29.67% up from its 52 week low.

What is Entera Bio Ltd's market capitalisation today?

Entera Bio Ltd market capitalisation is $0.00T as on .

How to invest in Entera Bio Ltd Stock (ENTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Entera Bio Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Entera Bio Ltd Shares that will get you 1.2712 shares as per Entera Bio Ltd share price of $1.18 per share as on April 17, 2026 at 1:29 am IST.

What is the minimum amount required to buy Entera Bio Ltd Stock (ENTX) from India?

Indian investors can start investing in Entera Bio Ltd (ENTX) shares with as little as ₹93.289 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹932.89 in Entera Bio Ltd stock (as per the Rupee-Dollar exchange rate as on ). Based on Entera Bio Ltd share’s latest price of $1.18 as on April 17, 2026 at 1:29 am IST, you will get 8.4746 shares of Entera Bio Ltd. Learn more about fractional shares .

What are the returns that Entera Bio Ltd has given to Indian investors in the last 5 years?

Entera Bio Ltd stock has given -60% share price returns and 25.08% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?